Posts Tagged ‘MIGS’
Mixing MIGS & Meds
Long gone are the days where glaucoma surgery meant an invasive procedure with the likelihood of a serious complication developing down the road – while trabeculectomy is still a viable option, its side-effect profile is relegating it to more of a final option. These days, surgeons are much more likely to recommend minimally invasive glaucoma…
Read MoreIridex Makes its Move in Glaucoma
Over the past couple of years, there has been no shortage of positive news about the glaucoma space. While minimally invasive glaucoma surgery (MIGS) has totally captured the limelight, Iridex Corp. has quietly begun to build momentum with its Cyclo G6 laser. Iridex has a more than 30-year track record in laser photocoagulation and a…
Read MoreAvedro Finally Secures FDA Approval
On Monday, Avedro Inc. announced the US Food and Drug Administration finally gave a green light for its KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus. This is a story we’ve been following at OIS.net. According to the company, keratoconus is a progressive thinning and distortion of the cornea. It is…
Read MoreLewis Handicaps MIGS Market & Explains Glaucoma’s Emergence
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 077″] Glaucoma specialist Dr. Richard Lewis says glaucoma was once the “boring step sister” of the ophthalmology world. But now the chief medical officer of Aerie says the rise in devices and drugs has made glaucoma one of the coolest kids in ophthalmology’s school yard. 10 Top Topics in this OIS…
Read MoreEye on Five – February Edition 2016
The Transcend acquisition tops the list, but February was a promising month for ophthalmology. Alcon Leaps into MIGS with Transcend With its acquisition of Transcend Medical and its CyPass Micro-Stent platform for glaucoma, Novartis aims to kick start the lackluster growth of its Alcon unit by tapping into the high-growth micro-invasive glaucoma surgery device market…
Read MoreKOL Corner: Alcon, Transcend & Glaucoma 360
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 074″] Glaucoma once might have been a boring or sleepy sub-specialty of ophthalmology, but recent technical advances and significant bets placed by large strategics including Alcon’s planned ac-quisition of Transcend has injected the sector with enthusiasm and energy. OIS Podcast, in our new KOL Corner features, talks with leading glaucoma specialists…
Read MoreAlcon Makes Big Move in MIGS
With Transcend, Alcon Gains a Foothold in Glaucoma Device Market Contributed by Larry Haimovitch and Richard Mark Kirkner With its move to acquire Transcend Medical and its CyPass Micro-Stent platform for glaucoma, Novartis aims to kick start the lackluster growth of its Alcon unit by tapping into the high-growth micro-invasive glaucoma surgery (MIGS) device market…
Read MoreHow MIGS is Remaking the Glaucoma Market
Glaucoma is a chronic degenerative disease whose incidence increases significantly with age. According to the World Health Organization, it is the second leading cause of blindness in the world. Estimates put the total number of suspected cases of glaucoma at over 60 million worldwide. Glaucoma medications, which generate about $5 billion in annual sales globally,…
Read MoreFDA Looking to Follow Up on Year of “Firsts”
If you’re an executive at an ophthalmic drug development company and desire a frank discussion on regulatory issues that are critical to your business, you’d certainly jump at the chance to invite to breakfast Wiley Chambers, MD, deputy director of the Division of Transplant and Ophthalmology Products within FDA’s Center for Drug Evaluation and Research.…
Read MoreGlaucoma Getting a Wake-Up Call
SAN FRANCISCO — Thanks to a pending boom in minimally invasive glaucoma surgery (MIGS) devices, the global glaucoma device market is poised to come out of its long slumber and triple over the next five years, participants at the fifth annual “Glaucoma 360-New Horizons Forum” heard. Sponsored by the non-profit Glaucoma Research Foundation, the forum…
Read MoreMicroOptx Pursues New MIGS Approach
Chris Pulling, CEO of MicroOptx, tells OISTV about its Brown Glaucoma Implant (new name pending). The implant is used to lower IOP by draining aqueous fluid. Unlike other implants, which divert fluid to other chambers of the eye, MicroOptx is shunts the fluid to the tear film. Speaking With: Chris Pulling Chris was most recently…
Read MoreTranscend Medical
The year 2015 represented a milestone for Transcend Medical – it completed a milestone study and filed a Premarket Approval for a minimally invasive glaucoma surgery (MIGS) device, the CyPass Micro-Stent. The CyPass is a next-generation device designed to enhance aqueous outflow to the suprachoroidal space by being placed in the supraciliary space (an ab…
Read More